Skip to content

A clinical study on relieving postoperative pain in patients undergoing craniotomy with bupivacaine liposome scalp nerve block

A clinical study on relieving postoperative pain in patients undergoing craniotomy with bupivacaine liposome scalp nerve block

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500105522
Enrollment
Unknown
Registered
2025-07-04
Start date
2023-07-10
Completion date
Unknown
Last updated
2025-07-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diseases that require craniotomy surgery

Interventions

Intravenous analgesia group:No scalp nerve block is performed, traditional anesthesia is received, and a standardized anesthesia regimen is performed, which includes target controlled infusion of prop
Ropivacaine group:Targeted infusion of propofol 3-4 ug/ml, fentanyl 2-3 ug/kg iv, and cisatracurium 0.2mg/kg were used for anesthesia induction. After anesthesia induction, 0.33% ropivacaine was used
Bupivacaine liposome scalp nerve block group:Targeted infusion of propofol 3-4 ug/ml, fentanyl 2-3 ug/kg iv, and cisatracurium 0.2mg/kg were used for anesthesia induction. After anesthesia induction,

Sponsors

The First Affiliated Hospital of Guangxi Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Adult patients between the ages of 18 and 60 who underwent craniotomy; 2. ASA Levels I–III.

Exclusion criteria

Exclusion criteria: 1. Glasgow Coma Scale (GCS) less than 15 points; 2. Allergy to local anesthetics; 3. Contraindications to scalp nerve block; 4. Receiving long-term analgesia or corticosteroid therapy; 5. Opioid tolerance (defined as >30 mg morphine equivalent per day taken by the patient); 6.BMI> 30kg/m^2; 7. Presence of liver and kidney dysfunction and severe cardiopulmonary diseases; 8. Patients who are not cooperative or unwilling to enroll.

Design outcomes

Primary

MeasureTime frame
VAS pain score;

Secondary

MeasureTime frame
Use of analgesic drugs;Demographic data;

Countries

China

Contacts

Public ContactLai Jian

The First Affiliated Hospital of Guangxi Medical University

304664467@qq.com+86 134 8109 6925

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026